Subscribe to magazine
Subscribe to newsletters
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Radiation Dose management
Intravascular imaging systems
Peripheral Artery Disease
Cardiac resynchronization therapy devices (CRT)
Implantable cardioverter defibrillators (ICD)
Leads, implantable devices
Heart Valve Technology
Left atrial appendage (LAA) occluders
Structural heart occluders/closure devices
University of Colorado Hospital
Henry Ford Hospital
Baylor Scott and White Heart Hospital
Merck & Co.
May 04, 2010
Companies Partner to Produce Generic Zetia
May 4, 2010 – A deal has been struck to produce a generic version of Merck & Company’s Zetia (ezetimibe). In the...
March 19, 2010
Factor Xa Inhibitor Reduced Bleeding Compared to Warfarin in AF Patients
March 19, 2010 – An experimental factor Xa inhibitor given to patients with non-valvular atrial fibrillation (AF) or...
November 20, 2009
Trial Evaluates New Anti-Platelet in Preventing Cardiovascular Events
November 18, 2009 – Patient enrollment was recently completed in the TRA 2 P-TIMI 50 clinical trial to study SCH 530348...
July 10, 2009
Merck, Portola to Develop Oral Anticoagulant for Cardiovascular Disease
July 10, 2009 – Merck & Co. Inc. and Portola Pharmaceuticals Inc. this week signed an exclusive global...
April 10, 2009
Merck, Cardiome Sign License Agreement for Investigational Drug for Treatment of Atrial Fibrillation
April 10, 2009 - Merck & Co., Inc. and Cardiome Pharma Corp.
January 29, 2008
Iroko Acquires Rights to Merck Drug for PTCA Patients
January 30, 2008 - Iroko Pharmaceuticals (Iroko) acquired all non-U.S. commercial rights to Aggrastat (tirofiban HCl)...
Scranton Gillette Communications
. All Rights Reserved.
Topics We Cover
Terms and Conditions